Marble Harbor Investment Counsel LLC Sells 1,873 Shares of Johnson & Johnson $JNJ

Marble Harbor Investment Counsel LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 52,556 shares of the company’s stock after selling 1,873 shares during the period. Johnson & Johnson comprises about 1.3% of Marble Harbor Investment Counsel LLC’s investment portfolio, making the stock its 23rd biggest holding. Marble Harbor Investment Counsel LLC’s holdings in Johnson & Johnson were worth $13,914,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Allworth Financial LP lifted its position in shares of Johnson & Johnson by 14.7% in the 3rd quarter. Allworth Financial LP now owns 416,392 shares of the company’s stock worth $105,751,000 after buying an additional 53,434 shares during the last quarter. Fisher Asset Management LLC boosted its holdings in shares of Johnson & Johnson by 11.5% in the 3rd quarter. Fisher Asset Management LLC now owns 14,837,126 shares of the company’s stock valued at $3,927,981,000 after buying an additional 1,530,070 shares during the period. Altar Rock LLC grew its position in shares of Johnson & Johnson by 4.5% during the 3rd quarter. Altar Rock LLC now owns 958 shares of the company’s stock valued at $250,000 after buying an additional 41 shares during the last quarter. Legacy Trust grew its position in shares of Johnson & Johnson by 3.5% during the 3rd quarter. Legacy Trust now owns 46,302 shares of the company’s stock valued at $12,650,000 after buying an additional 1,549 shares during the last quarter. Finally, Warburton Capital Management LLC raised its stake in Johnson & Johnson by 12.5% during the third quarter. Warburton Capital Management LLC now owns 1,132 shares of the company’s stock worth $301,000 after acquiring an additional 126 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 1.2%

Johnson & Johnson stock opened at $283.69 on Friday. The company has a 50-day simple moving average of $266.83 and a 200-day simple moving average of $249.54. The firm has a market capitalization of $682.93 billion, a P/E ratio of 42.98, a P/E/G ratio of 2.77 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. Johnson & Johnson has a one year low of $193.45 and a one year high of $286.08.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter last year, the company earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 1.9%. Johnson & Johnson’s dividend payout ratio is 81.21%.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.16% of the stock is currently owned by company insiders.

Recent Johnson & Johnson Headlines

Here are a few of the latest headlines about JNJ:

• Positive Sentiment: J&J reported favorable Phase 3 results for CAPLYTA in adults with bipolar I disorder, with the drug providing rapid relief of manic symptoms. Positive data could strengthen the case for expanding the medicine’s use and future sales. Johnson & Johnson Reports Favorable Data For Bipolar Study
• Positive Sentiment: The company is backing Francis Medical as it advances its Vanquish water-vapor therapy device for prostate cancer through the FDA premarket approval process. J&J also led a $100 million funding round for Delix Therapeutics, supporting development of psychedelic-inspired depression treatments. The deals broaden its potential reach in cancer care and psychiatry, though both carry development and regulatory risk. J&J leads Francis Medical investment to fund prostate cancer device Johnson & Johnson backs new cancer device and leads $100 million depression bet
• Neutral Sentiment: State Street’s Health Care SPDR added J&J shares on Nov. 10 as part of a broader increase across all of the fund’s holdings. The purchase provides an institutional-demand datapoint but was not specific to J&J. State Street Health Care SPDR adds Johnson & Johnson

Analysts Set New Price Targets

A number of equities analysts have issued reports on JNJ shares. Weiss Ratings cut shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a report on Friday, October 23rd. Wells Fargo & Company lifted their target price on Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a research note on Friday, October 16th. Johnson Rice lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, October 21st. Erste Group Bank cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. Finally, Raymond James Financial set a $280.00 price target on Johnson & Johnson in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $275.92.

Johnson & Johnson Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.